In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Deals in Depth: October 2008

Executive Summary

October 2008 dealmaking highlights: China Medical's purchase of the HPV-DNA biosensor chip and SPR technology from Molecular Diagnostics Technologies for $345 million was the leading alliance in terms of $ value. Eli Lilly emerged as the mystery bidder for ImClone, defeating BMS and signing a definitive agreement to buy the biotech for $6.5 billion. In October no FOPOs or IPOs were completed in either industry. Private placements, mostly from early- and late-VC rounds, in biopharmas decreased 31% from last month to $358 million while investments in medical devices were up 1.5x to $296 million.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

IV003045

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel